Project Grant R21CA296748
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $434K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, supports research to develop a novel CAR T-cell therapy for patients with hepatocellular carcinoma (liver cancer). The $470,759 award, commencing on September 1, 2025, aims to prevent CAR T-cell exhaustion and improve the antitumor activity of GPC3-CAR T-cells through the precise, on-demand control...
- This federal Project Grant award of $456,414 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support the development and clinical evaluation of B7-H3 chimeric antigen receptor (CAR) T cells for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults. The grant, awarded to Seattle Children's Research Institute, will fund a Phase 2 clinical trial to assess the efficacy and safety of repeatedly administering the B7-H3 CAR T cells...
- The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...
- This $177,180 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Fred Hutchinson Cancer Center in Seattle, Washington supports research to improve engineered TCR-T cell therapy for solid tumors. The key goals are to investigate whether engineered TCR-T cells form PD-1+TCF1+ stem-like progenitor exhausted T cell populations in tumor-draining lymph nodes, similar to endogenous tumor-specific T cells. This could impact the long-term persistence...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- The federal Project Grant award titled "Investigating and Targeting NSD2 Mutation-Driven Leukemia Transformation" is funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) in the amount of $484,405.00 with a performance period from September 1, 2025 to August 31, 2030. The grant was awarded to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, a private non-profit academic medical center in Pennsylvania. The project aims to...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
- The National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), awarded a $530,106 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, awarded on September 11, 2025, supports research aimed at understanding and targeting polyamine metabolism in leukemia stem cells (LSCs) to improve outcomes for patients with acute myeloid leukemia (AML). The overarching goal is to develop LSC-directed therapies that can help overcome...